RecruitingPhase 2NCT04226950

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Lei Zhang, MD
Institute of Hematology & Blood Diseases Hospital, China
Intervention
Recombinant Interferon Alpha(drug)
Enrollment
40 enrolled
Eligibility
19 years · All sexes
Timeline
2020 – 2024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04226950 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials